Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 15, 2017 CORR, GLAD, LBY, CDR, BRKR, B, Expected to Trade Higher After Bullish Insider Trading
March 15, 2017 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. CorEnergy Infrastructure Trust Inc. (NYSE:CORR), Gladstone Capital Corporation (NASDAQ:GLAD), Libbey Inc. (NYSE:LBY), Cedar Realty Trust Inc. (NYSE:CDR), Bruker Corporation (NASDAQ:BRKR), Barnes Group Inc. (NYSE:B) are all expected to go Higher as Buy signals have been generated by top insider trading patterns. The most important data elements considered when performing insider analysis are: Insiders Track Record - An insiders track record is best summarized by the Insider Score which ranges from 1 (least predictive) to 100 (most predictive) based on prior trading performance. In addition, the actual returns following the insiders prior trades are included to determine the potential magnitude of future returns. Insiders Role - Trades by higher-level insiders are generally more predictive than trades by lower level insiders. Higher-level insiders to include Chairman (CB), Chief Executive Officer (CEO), President (P), Chief Financial Officer (CFO), and Vice Chairman (VC).
The chart below displays the stocks expected to go Higher along with the insider name, position, predictive insider score, 6 month expected return and number of trading decisions included in the score.
Symbol Company Name Insider Name Role Shares Insider Score Avg 6 Month Return # of Dec. CORR CorEnergy Infrastructure Trust Inc. Sandring, Rebecca M O 305 76 37.5% 3 GLAD Gladstone Capital Corporation Marcotte, Robert L P 10,000 79 16.7% 4 LBY Libbey Inc. Foley, William A CEO 5,000 80 25.4% 2 CDR Cedar Realty Trust Inc. Schanzer, Bruce J CEO 14,000 95 16.2% 9 BRKR Bruker Corporation Laukien, Frank H CEO 2,300 98 17.0% 32 B Barnes Group Inc. Benanav, Gary G D 31 88 15.6% 7The insider buying report presents recent insider purchases, reported on Forms 3, 4, and 5 filed with the SEC. The transactions are aggregated to a 'decision' level which simplifies the data analysis. A decision is a grouping of buying or selling by an individual at the specified company.
CorEnergy Infrastructure Trust Inc. (NYSE:CORR) - COR Therapeutics, Inc. is engaged in the discovery, development and marketing of novel therapeutic products to establish new standards of care for treating and preventing acute and chronic cardiovascular diseases. The Company is marketing Integrilin to treat patients with acute cardiovascular disease. The Company is also developing a portfolio of drugs to treat and prevent a broad range of acute and chronic cardiovascular diseases and other conditions.
In addition to its commercial activities, the Company continues to pursue a wide array of research and development programs. These programs may have therapeutic potential for a variety of indications, including acute coronary syndromes, stroke, restenosis, cancer, and venous and arterial thrombosis.
Integrilin
Integrilin, COR Therapeutics' first product taken from discovery to commercialization, is a small synthetic peptide that blocks the platelet receptor GP IIb-IIIa to inhibit platelet aggregation. By blocking GP IIb-IIIa, Integrilin helps prevent thrombus formations from fully blocking coronary arteries, a situation that can lead to heart attack or death in patients with acute coronary syndromes or patients undergoing angioplasty procedures. Importantly, the effects of Integrilin are specific to platelets, thereby avoiding interference with other normal cardiovascular processes. Additionally, certain effects of Integrilin can be reversed once therapy with Integrilin is discontinued. Well over one million people in the United States annually are candidates for Integrilin therapy.
In May 1998, the United States Food and Drug Administration (FDA) approved Integrilin to treat patients who undergo angioplasty to open blood vessels. The FDA has also approved Integrilin to treat patients with intermittent chest pains, known as unstable angina, and patients suffering from non-Q-wave myocardial infarction, a form of heart attack, whether the doctor intends to treat these patients with medicines alone or with a subsequent angioplasty.
In January 2001, COR Therapeutics, Schering-Plough Ltd. and Schering Corporation (collectively, Schering) and Genentech, Inc., entered into an agreement to co-promote Integrilin with Genentech's fibrinolytic, or clot-dissolving drugs, TNKase (tenecteplase) and Activase (alteplase, recombinant), across the United States. The Company, Schering and Genentech have also agreed to an exclusive clinical collaboration for any future large-scale clinical trials that combine a fibrinolytic with drugs in the same class as Integrilin.
In collaboration with Schering and Genentech, the Company's cardiovascular sales forces educate the medical community about GP IIb-IIIa inhibitor therapy and market the use of Integrilin in such therapy. The Company jointly markets Integrilin to clinical cardiologists, interventional cardiologists and emergency medicine physicians. The Company also focuses on hospital pharmacy directors, formulary committee members, hospital administrators and nurses, all of whom might affect purchasing decisions.
Cromafiban
The Company has completed a series of Phase II clinical trials of cromafiban, an oral drug designed to prevent blood clotting. The Company has shown in clinical trials that cromafiban remains active in the body long enough to allow patients to take the drug only once a day. The Company also observed in these trials that the level of activity of the drug in the body does not vary greatly throughout a 24-hour period and that the drug can be taken with or without food. The most common complication observed during these trials was minor bleeding. At least one additional Phase II clinical trial would be required before COR Therapeutics could commence a larger Phase III clinical trial; however, the Company has not yet enrolled any patients in any clinical trials of cromafiban.
Growth Factor Inhibitor Programs
COR Therapeutics' growth factor inhibitor program is directed toward the discovery of inhibitors of certain growth factor receptors in the tyrosine kinase family, which the Company believes play .
Gladstone Capital Corporation (NASDAQ:GLAD) - Gladstone Capital Corporation is a business development company specializing in debt investments in senior loans, second lien loans, senior subordinated loans, junior subordinated loans, and mezzanine loans and equity investments in the form of common stock, preferred stock, limited liability company interests, or warrants. The fund also makes private equity investments in acquisitions, buyouts and recapitalizations, and refinancing existing debts. It targets small and medium-sized companies in United States. It invests in companies engaged in the consumer staples, media, and industrial sector. The fund seeks to invest between $7 million and $30 million in companies that have between $20 million and $500 million in sales. It prefers to acquire minority stakes and also prefers to take majority stake in its portfolio companies. It seeks to exit its investments through strategic acquisitions by other industry participants or financial buyers, initial public offerings of common stock, or other capital market transactions..
Libbey Inc. (NYSE:LBY) - Libbey Inc. designs, produces, and sells tableware and other products worldwide. It offers glass tableware products, including tumblers, stemware, mugs, bowls, vases, salt and pepper shakers, shot glasses, canisters, candleholders, and other items; storage ware; serve ware; bakeware; handmade glass tableware; and other components for original equipment manufacturers, such as blender jars, mixing bowls, and washing machine windows. The company also provides ceramic dinnerware products comprising plates, bowls, platters, cups, saucers, and other tabletop accessories; metal flatware consisting of knives, forks, spoons, and serving utensils; and metal hollowware, which consists of serving trays, pitchers, and other metal tabletop accessories. In addition, it distributes fine stemware and other drinkware assortments; upscale serve ware, decorative products, stemware, and drinkware for finer dining establishments; porcelain and bone China products; and tabletop and giftware products. The company offers its products under the Libbey, Libbey Signature, Masters Reserve, World Tableware, Syracuse China, Crisa, Royal Leerdam, and Crisal Glass brand names. It markets its products to foodservice distributors, mass merchants, department stores, retail distributors, national retail chains, specialty housewares stores, candle and food packers, decorators, breweries, distilleries, craft industries, gourmet food-packing companies, and companies using glass containers for candle and floral applications. Libbey Inc. was founded in 1818 and is headquartered in Toledo, Ohio..
Cedar Realty Trust Inc. (NYSE:CDR) - Cedar Realty Trust, Inc. is an independent equity real estate investment trust. The firm is primarily engaged in ownership, operation, development, and redevelopment of properties. It invests in the real estate markets of the United States predominantly in mid- Atlantic and Northeast coastal states. The firm primarily invests in supermarket-anchored shopping centers. It benchmarks the performance of its portfolio against the NAREIT All Equity REIT Index and the Russell 2000 Index. Cedar Realty Trust, Inc. was founded in 1984 and is based in Port Washington, New York..
Bruker Corporation (NASDAQ:BRKR) - Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and various other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts..
Barnes Group Inc. (NYSE:B) - Barnes Group Inc. operates as an industrial and aerospace manufacturer and service provider, serving a range of end markets and customers. The company operates in two segments, Industrial and Aerospace. The Industrial segment offers precision parts, products, and systems for applications serving various customers in end-markets, such as transportation, industrial equipment, consumer products, packaging, electronics, medical devices, and energy. This segment also manufactures and supplies precision mechanical products, including mechanical springs, high-precision punched and fine-blanked components, and retention rings; fine hairsprings for electronics and instruments and heavy-duty springs for machinery; nitrogen gas springs and manifold systems used to control stamping presses; and hot runner systems, mold cavity sensors and process control systems, and precision high cavitation mold and cube mold assemblies. The Aerospace segment produces fabricated and precision-machined components and assemblies for original equipment manufacturer turbine engine, airframe, and industrial gas turbine builders, as well as for the military. It also offers maintenance, repair, and overhaul services for jet engine components to turbine engine manufacturers, commercial airlines, and the military. In addition, this segment manufactures aerospace aftermarket spare parts. The company sells its products primarily through its direct sales force and distribution channels worldwide. Barnes Group Inc. was founded in 1857 and is headquartered in Bristol, Connecticut..
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com